Page last updated: 2024-08-21

quinazolines and Familial Nonmedullary Thyroid Cancer

quinazolines has been researched along with Familial Nonmedullary Thyroid Cancer in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Courtier, B; Hadoux, J1
Cohen, PR; Udkoff, J1
Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M1
Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H1
Bible, KC1
Awada, A; Bastholt, L; Bonichon, F; de la Fouchardiere, C; Gómez, JM; Krause, T; Leboulleux, S; Leenhardt, L; Licour, M; Schlumberger, MJ; Soufflet, C; Tennvall, J1

Reviews

1 review(s) available for quinazolines and Familial Nonmedullary Thyroid Cancer

ArticleYear
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.
    Dermatology online journal, 2016, Oct-15, Volume: 22, Issue:10

    Topics: Aged; Carcinoma; Carcinoma, Papillary; Humans; Immunohistochemistry; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Piperidines; Quinazolines; Skin Neoplasms; Thoracic Wall; Thyroid Cancer, Papillary; Thyroid Neoplasms

2016

Trials

1 trial(s) available for quinazolines and Familial Nonmedullary Thyroid Cancer

ArticleYear
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Double-Blind Method; Electrocardiography; ErbB Receptors; Female; Heart Conduction System; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Survival Analysis; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult

2012

Other Studies

5 other study(ies) available for quinazolines and Familial Nonmedullary Thyroid Cancer

ArticleYear
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
    Bulletin du cancer, 2021, Volume: 108, Issue:11

    Topics: Anilides; Antineoplastic Agents; Carcinoma, Medullary; Drug Approval; Humans; Mutation; Phenylurea Compounds; Piperidines; Precision Medicine; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Quinolines; Thyroid Cancer, Papillary; Thyroid Neoplasms

2021
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    European journal of endocrinology, 2014, Volume: 170, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome

2014
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.
    Pathology international, 2011, Volume: 61, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome

2011
Treating advanced radioresistant differentiated thyroid cancer.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms

2012
First do no harm: counting the cost of chasing drug efficacy.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms

2012